Québec City, Québec, Canada - Feldan Therapeutics, a leading biopharmaceutical company specializing in intracellular delivery of therapeutics, announced today the successful completion of its Series B funding round, raising an impressive $16.5 million. The funding was secured from renowned investors Amgen and GC Cell, further validating the tremendous potential of Feldan's innovative technologies and treatment development.

Feldan Therapeutics is headquartered in Québec City, Québec, and is at the forefront of biotechnology research. The company has developed a groundbreaking proprietary peptide-based technology, known as the Feldan Shuttle, which enables the safe and efficient delivery of various therapeutic compounds directly into cells. This cutting-edge technology represents a significant leap forward, granting access to intracellular components previously beyond the reach of existing drugs.

Feldan Therapeutics has always placed a strong emphasis on internal research and innovation. The success of the Feldan Shuttle further underscores the company's commitment to revolutionizing the field of therapeutics and transforming patient outcomes. By unlocking the potential of intracellular delivery, Feldan Therapeutics is poised to develop a new generation of therapies that have the ability to target previously untreatable diseases.

"We are delighted to have raised $16.5 million in this Series B funding round, with the support and confidence of esteemed investors such as Amgen and GC Cell," said Francois-Thomas Michaud, Founder of Feldan Therapeutics. "This significant investment will enable us to accelerate our research and bring our innovative treatments one step closer to patients who need them the most."